Quick Answer
MOLECULAR PARTNERS AG reported R&D Expense of $40.19 million for fiscal year 2025.
MOLECULAR PARTNERS AG R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $40.19M | -17.3% |
| 2024 | $48.60M | -0.4% |
| 2023 | $48.78M | -3.9% |
| 2022 | $50.75M | -8.9% |
| 2021 | $55.72M | -0.6% |
| 2020 | $56.08M | +28.9% |
| 2019 | $43.50M | — |
- MOLECULAR PARTNERS AG showed a decrease of -17.3% in R&D Expense compared to the prior fiscal year.
- Over the 2019–2025 period, MOLECULAR PARTNERS AG’s r&d expense has declined by 7.6% (from $43.50 million to $40.19 million).
- The most recent figure is from MOLECULAR PARTNERS AG’s fiscal year 2025 report (Form 20-F), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: